Legend Biotech Corp ADR
Closed
SectorHealthcare
20.85 -4.45
Overview
Share price change
24h
Min
21.64
Max
21.99
Income | 88M 33M |
|---|---|
Sales | 82M 388M |
EPS | 0.09 |
Profit margin | 8.568 |
Employees | 3,200 |
EBITDA | 92M 60M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +120.3% upside |
Next Earnings | 11 Nov 2026 |
|---|
Market Cap | 4.9M 4B |
|---|---|
Previous open | 25.3 |
Previous close | 20.85 |
News Sentiment
By Acuity
100%
0%
328 / 340 Healthcare
Legend Biotech Corp ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Legend Biotech Corp ADR Forecast
Price Target
By TipRanks
120.3% upside
12 Months Forecast
Average 48.07 USD 120.3%
High 78 USD
Low 24 USD
Based on 10 Wall Street analysts offering 12 month price targets forLegend Biotech Corp ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Legend Biotech Corp ADR
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.